Protocol Ledger

NCT06378177 · Phase II · ACTIVE NOT RECRUITING

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventional Phase II clinical trial protocol NCT06378177 sponsored by Lyvgen Biopharma Holdings Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-21 Enrollment: 64 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06378177
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)64 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06378177
Protocol FieldVerified Registry Value
NCT IdentifierNCT06378177
Consolidated Lead SponsorLyvgen Biopharma Holdings Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment64 participants (ESTIMATED)
Registered Start Date2024-06-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI